Details for Patent: 10,117,951

Which drugs does patent 10,117,951 protect, and when does it expire?

Patent 10,117,951 protects NOXAFIL and ZULRESSO and is included in two NDAs.

This patent has twenty-nine patent family members in thirteen countries.

Summary for Patent: 10,117,951

Scope and claims summary:

Title:	Sulfoalkyl ether cyclodextrin compositions
Abstract:	SAE-CD compositions are provided, along with methods of making and using the same. The SAE-CD compositions comprise a sulfoalkyl ether cyclodextrin having an absorption of less than 0.5 A.U. due to a drug-degrading agent, as determined by UV/vis spectrophotometry at a wavelength of 245 nm to 270 nm for an aqueous solution containing 300 mg of the SAE-CD composition per mL of solution in a cell having a 1 cm path length.
Inventor(s):	Antle; Vincent D. (Olathe, KS)
Assignee:	CyDex Pharmaceuticals, Inc. (San Diego, CA)
Application Number:	14/954,772
Patent Claim Types: see list of patent claims	Composition; Formulation;

Drugs Protected by US Patent 10,117,951

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Merck Sharp Dohme	NOXAFIL	posaconazole	SOLUTION;INTRAVENOUS	205596-001	Mar 13, 2014	AP	RX	Yes	Yes	10,117,951		Y
Sage Therap	ZULRESSO	brexanolone	SOLUTION;INTRAVENOUS	211371-001	Jun 17, 2019		RX	Yes	Yes	10,117,951		Y

International Family Members for US Patent 10,117,951

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2009241858
Brazil	PI0905080
Canada	2702603
Canada	2771879
China	101959508